EGFR and neoplasm: Tumor uptake of 111In-nimotuzumab followed a similar trend with high uptake (12.4 ± 1.3 %IA/g) in EGFR positive DLD-1 xenograft (Figure 3c) and less uptake (3.4 ± 1.1 %IA/g) in EGFR negative MDA-MB-435 xenograft (Figure 3d).